arrow
R

Richard Marcellus

ontario institute for cancer research
H指数:32
被引数:5,490

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors

基于结构的硫酰氨基-乙基-4-氧代-3,4-二氢-7H-吡咯并[2,3-d]嘧啶酰胺和磺酰胺类化合物的发现及其作为强效B-细胞淋巴瘤6 (BCL6)-BTB抑制剂的用途

2025-11-130
PRE
Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma

靶向非同源末端连接与辐射之间的合成致死作用以治疗极高危性髓母细胞瘤

2025-06-240
OAAI
Discovery of Nanomolar DCAF1 Small Molecule Ligands
2023-03-2220
OAAI
The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors
2023-03-21222
OAAI
Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma (vol 64, pg 11129, 2021)
2021-12-281
PREAI
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
2021-07-2341
OAAI
Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma
2021-07-2217
PREAI
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
2021-02-042
OA
A drug discovery platform to identify compounds that inhibit EGFR triple mutants
2020-02-2436
OAAI
Discovery of OICR-10268: A potent and selective BCL6 inhibitor
2019-07-010
PRE
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)
2016-03-0981
PREAI